22:18 , Aug 1, 2018 |  BC Extra  |  Company News

Management tracks: Hologic, Tricidia

Hologic Inc. (NASDAQ:HOLX) said Bob McMahon has departed as CFO to become CFO at Agilent Technologies Inc. (NYSE:A). The diagnostics company promoted Chief Accounting Officer Karleen Oberton to CFO. Metabolic acidosis play Tricida Inc. (NASDAQ:TCDA)...
21:15 , May 2, 2017 |  BC Extra  |  Company News

Management tracks

The Association of the British Pharmaceutical Industry named Lisa Anson president. She is president of the U.K. and Ireland division at AstraZeneca plc (LSE:AZN; NYSE:AZN). Effective June 30, President and CEO C. Randal Mills is...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Financial News

Concordia completes private placement of senior notes

Concordia International Corp. (NASDAQ:CXRX; TSX:CXR), Oakville, Ontario   Business: Cancer, Neurology, Gastrointestinal   Date completed: 2016-10-06   Type: Private placement of senior notes   Raised: $350 million   Investor: Institutional investors   Note: The senior...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Company News

ANI Pharmaceuticals sales and marketing update

ANI launched a generic version of Nilandron nilutamide from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) in the U.S. The oral testosterone blocker is marketed to treat metastatic prostate cancer. Under a 2013 deal, Sanofi granted Covis...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

Amdipharm Mercury, Concordia Healthcare deal

Concordia completed its acquisition of fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for $3.1 billion, including $1.4 billion in debt. The acquisition consists of L800 million ($1.2 billion) in cash, $47.5...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

Amdipharm Mercury, Concordia Healthcare deal

Concordia will acquire fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for up to $3.6 billion, including debt. The acquisition consists of L800 million ($1.2 billion) in cash and 8.5 million of...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Financial News

Concordia Healthcare completes follow-on

Concordia Healthcare Corp. (TSX:CXR; NASDAQ:CXRX), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date completed: 2015-09-24   Type: Follow-on   Raised: $520 million   Shares: 8 million   Price: $65   Shares after offering: 42.3...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Company News

Covis, Concordia Healthcare deal

Concordia completed its acquisition of Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash (see BioCentury, March 16). Covis Pharma S.a.r.l. , Zug, Switzerland   Concordia Healthcare Corp. (TSX:CXR;OTCQX:CHEHF),...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Financial News

Concordia Healthcare completes private placement of senior notes

Concordia Healthcare Corp. (TSX:CXR; OTCQX:CHEHF), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date completed: 2015-04-13   Type: Private placement of senior notes   Raised: $735 million   Investor: Institutional investors   Note: The unsecured...